Abstract：Argininemia is a rare, autosomal recessive, metabolic disorder caused by an hereditary deficiency of hepatocytes arginase due to ARG1 gene defect. Arginase is the final enzyme in the urea cycle, catalyzing the hydrolysis of arginine to ornithine and urea. Research advances in the clinical manifestations, diagnosis, treatment, prenatal diagnosis and genetics of argininemia were reviewed in this paper. The clinical manifestations of patients with argininemia are complicated and nonspecific so that clinical diagnosis is usually difficult and delayed. Progressive spastic tetraplegia, seizures and cerebella atrophy are common clinical features of the disease. Blood amino acids analysis, arginase assay and ARG1 gene analysis are important to the diagnosis of argininemia. Early diagnosis and a protein-restricted diet with citrulline and benzoate supplements can contribute a lot to improve patient prognosis. With the application of liquid chromatography-tandem mass spectrometry in selective screening and newborn screening for inborn errors of metabolism, an ever-increasing number of patients with argininemia are detected at the asymptomatic or early stages.
Cederbaum SD, Yu H, Grody WW, Kern RM, Yoo P, Iyer RK. Arginases I and II: do their functions overlap?[J]. Mol Genet Metab, 2004, 81(Suppl 1): S38-S44.
[3]
Lee BH, Jin HY, Kim GH, Choi JH, Yoo HW. Argininemia presenting with progressive spastic diplegia[J]. Pediatr Neurol, 2011, 44(3): 218-220.
[4]
Seminara J, Tuchman M, Krivitzky L, Krischer J, Lee HS, Lemons C. Establishing a Consortium for the Study of Rare Diseases: The Urea Cycle Disorders Consortium[J]. Mol Genet Metab, 2010, 100(Suppl 1): S97-105.
[5]
Deignan JL, Cederbaum SD, Grody WW. Contrasting features of urea cycle disorders in human patients and knockout mouse models[J]. Mol Genet Metab, 2008, 93(1): 7-14.
[6]
Nagata N, Matsuda I, Oyanagi K. Estimated frequency of urea cycle enzymopathies in Japan[J]. Am J Med Genet, 1991, 39(2): 228-229.
Segawa Y, Matsufuji M, Itokazu N, Utsunomiya H, Watanabe Y, Yoshino M, et al. Long-term survival case of arginase deficiency with severe multicystic white matter and compound mutations[J]. Brain Dev, 2011, 33(1): 45-48.
[9]
Hertecant JL, Al-Gazali LI, Karuvantevida NS, Ali BR. A novel mutation in ARG1 gene is responsible for arginase deficiency in an Asian family[J]. Saudi Med J, 2009, 30(12): 1601-1603.
Zytkovicz TH, Fitzgerald EF, Marsden D, Larson CA, Shih VE, Johnson DM, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program[J] . Clin Chem, 2001, 47(11): 1945-1955.
[12]
Marsden D. Expanded newborn screening by tandem mass spectrometry: the Massachusetts and New England experience[J]. Southeast Asian J Trop Med Public Health, 2003, 34(Suppl 3): 111-114.
Carvalho DR, Brum JM, Speck-Martins CE, Ventura FD, Navarro MM, Coelho KE, et al. Clinical features and neurologic progression of hyperargininemia[J]. Pediatr Neurol, 2012, 46(6): 369-374.
[17]
Scholl-Burgi S, Baumgartner Sigl S, Haberle J, Haberlandt E, Rostásy K, Ertl C, et al. Amino acids in CSF and plasma in hyperammonaemic coma due to arginase1 deficiency [J]. J Inherit Metab Dis, 2008, 31(Suppl 2): S323-328.
Cohen YH, Bargal R, Zeigler M, Markus-Eidlitz T, Zuri V, Zeharia A. Hyperargininemia: a family with a novel mutation in an unexpected site[J]. JIMD Rep, 2012, 5: 83-88.
[20]
Gomes Martins E, Santos Silva E, Vilarinho S, Saudubray JM, Vilarinho L. Neonatal cholestasis: an uncommon presentation of hyperargininemia [J]. J Inhert Metab Dis, 2010, 33(Suppl 3): S503-S506.
[21]
Scaglia F, Lee B. Clinical, biochemical, and molecular spectrum of hyperargininemia due to arginase I deficiency [J]. Am J Med Genet Part C, 2006, 142C (2): 113-120.
[22]
Hewson S, Clarke JT, Cederbaum S. Prenatal diagnosis for arginase deficiency: a case study [J]. J Inherit Metab Dis, 2003, 26(6): 607-610.
[23]
Jain-Ghai S, Nagamani SC, Blaser S, Siriwardena K, Feigenbaum A. Arginase I deficiency: severe infantile presentation with hyperammonemia: more common than reported?[J]. Mol Genet Metab, 2011, 104(1-2): 107-111.
Deignan JL, De Deyn PP, Cederbaum SD, Fuchshuber A, Roth B, Gsell W, et al. Guanidino compound levels in blood, cerebrospinal fluid, and post-mortem brain material of patients with argininemia[J]. Mol Genet Metab, 2010, 100(Suppl 1): S31-36.
[26]
Gungor S, Akinci A, Firat AK, Tabel Y, Alkan A. Neuroimaging findings in hyperargininemia[J]. J Neuroimaging, 2008, 18(4): 457-462.
[27]
Jay A, Seeterlin M, Stanley E, Grier R. Case report of argininemia: the utility of the arginine/ornithine ratio for newborn screening (NBS)[J]. JIMD Rep, 2013, 9: 121-124.
[28]
Kuhara T, Inoue Y, Ohse M, Krasnikov BF, Cooper AJ. Urinary 2-hydroxy-5-oxoproline, the lactam form of α-ketoglutaramate, is markedly increased in urea cycle disorders[J]. Anal Bioanal Chem, 2011, 400(7): 1843-1851.
[29]
Kanda H, Sumi D, Endo A, Toyama T, Chen CL, Kikushima M, et al. Reduction of arginase I activity and manganese levels in the liver during exposure of rats to methylmercury: a possible mechanism[J]. Arch Toxicol, 2008, 82(11): 803-808.
Korman SH, Gutman A, Stemmer E, Kay BS, Ben-Neriah Z, Zeigler M. Prenatal diagnosis for arginase deficiency by second-trimester fetal erythrocyte arginase assay and first-trimester ARG1 mutation analysis[J]. Prenat Diagn, 2004, 24(11): 857-860.
Carvalho DR, Brand GD, Brum JM, Takata RI, Speck-Martins CE, Pratesi R. Analysis of novel ARG1 mutations causing hyperargininemia and correlation with arginase I activity in erythrocytes[J].Gene, 2012, 509(1): 124-130.
[34]
Vockley JG, Goodman BK, Tabor DE, Kern RM, Jenkinson CP, Grody WW, et al. Loss of function mutations in conserved regions of the human arginase I gene [J]. Biochem Mol Med, 1996, 59(1): 44-51.
[35]
Haraguchi Y, Aparicio JM, Takiguchi M, Akaboshi I, Yoshino M, Mori M, et al. Molecular basis of argininemia. Identification of two discrete frame-shift deletions in the liver-type arginase gene[J]. J Clin Invest, 1990, 86(1): 347-350.
[36]
Grody WW, Klein D, Dodson A E, Kern RM, Wissmann PB, Goodman BK, et al. Molecular genetic study of human arginase deficiency[J]. Am J Hum Genet, 1992, 50(6): 1281-1290.
[37]
Uchino T, Haraguchi Y, Aparicio JM, Mizutani N, Higashikawa M, Naitoh H, et al. Three novel mutations in the liver-type arginase gene in three unrelated Japanese patients with argininemia[J]. Am J Hum Genet, 1992, 51(6): 1406-1412.
[38]
Haberle J, Koch HG. Genetic approach to prenatal diagnosis in urea cycle defects[J]. Prenat Diagn, 2004, 24(5): 378-383.
[39]
Uchino T, Snyderman SE, Lambert M, Qureshi IA, Shapira SK, Sansaricq C, et al. Molecular basis of phenotypic variation in patients with argininemia[J]. Hum Genet, 1995, 96(3): 255-260.
[40]
Cardoso ML, Martins E, Vasconcelos R, Vilarinho L, Rocha J. Identification of a novel R21X mutation in the liver-type arginase gene (ARG1) in four Portuguese patients with argininemia[J]. Hum Mutat, 1999, 14(4): 355-356.
[41]
Vockley JG, Tabor DE, Kern RM, Goodman BK, Wissmann PB, Kang DS, et al. Identification of mutations (D128G, H141L) in the liver arginase gene of patients with hyperargininemia [J]. Hum Mutat, 1994, 4(2): 150-154.
[42]
Edwards RL, Moseley K, Watanabe Y, Wong LJ, Ottina J, Yano S. Long-term neurodevelopmental effects of early detection and treatment in a 6-year-old patient with argininaemia diagnosed by newborn screening[J]. J Inherit Metab Dis, 2009, 32(Suppl 1): S197-200.
[43]
Mitchell S, Ellingson C, Coyne T, Hall L, Neill M, Christian N, et al. Genetic variation in the urea cycle: a model resource for investigating key candidate genes for common diseases[J]. Hum Mutat, 2009, 30(1): 56-60.
Boles RG, Stone ML. A patient with arginase deficiency and episodic hyperammonemia successfully treated with menses cessation[J]. Mol Genet Metab, 2006, 89(4): 390-391.
[46]
Romero PA, Stone E, Lamb C, Chantranupong L, Krause A, Miklos A, et al. SCHEMA designed variants of human arginase I & II reveal sequence elements important to stability and catalysis[J]. ACS Synth Biol, 2012, 1(6): 221-228.
[47]
Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, et al. Phase II study of pegylated arginine eiminase for nonresectable and metastatic hepatocellular carcinoma[J]. J Clin Oncol, 2010, 28 (13): 2220-2226.
[48]
McKay TR, Rahim AA, Buckley SM, Ward NJ, Chan JK, Howe SJ, et al. Perinatal gene transfer to the liver[J]. Curr Pharm Des, 2011, 17(24): 2528-2541.
[49]
Meyburg J, Das AM, Hoerster F, Lindner M, Kriegbaum H, Engelmann G, et al. One liver for four children: first clinical series of liver cell transplantation for severe neonatal urea cycle defects [J]. Transplantation, 2009, 87(5): 636-641.
[50]
Hughes RD, Mitry RR, Dhawan A. Hepatocyte transplantation for metabolic liver disease: UK experience [J]. J R Soc Med, 2005, 98(8): 341-345.
[51]
Pietrosi G, Vizzini GB, Gruttadauria S, Gridelli B. Clinical applications of hepatocyte transplantation [J]. World J Gastroenterol, 2009, 15 (17): 2074-2077.
[52]
Meyburg J, Hoffmann GF. Liver, liver cell and stem cell transplantation for the treatment of urea cycle defects [J]. Mol Genet Metab, 2010, 100(Suppl 1): S77-S83.
Gau CL, Rosenblatt RA, Cerullo V, Lay FD, Dow AC, Livesay J, et al. Short-term correction of arginase deficiency in a neonatal murine model with a helper-dependent adenoviral vector [J]. Mol Ther, 2009, 17(7): 1155-1163.
